Pricing Log in Create free account
Saturday 17 October 2026 Export PFE’s income statement to Excel — free account

Pfizer Inc.

PFE Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.

29.58 0.14 +0.48%
Market cap
$167.8B
P/E
38.9×
Fwd P/E
12.2×
Dividend yield
5.81%
F-score
6/9
Altman Z
2.03
Beneish M
−2.52
Dividend safety
28/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Pfizer Inc. (PFE) EV/Sales

Alert me on EV/Sales

As of 16 October 2026, Pfizer Inc. (PFE) trades at a EV/Sales of 3.5×. Over the past ten years it has ranged from 2.3× (March 2023) to 8.7× (December 2020); the current reading is higher than 31% of that period. That is below the Drug Manufacturers General industry median of 4.0× and in line with the Healthcare sector median of 3.4×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 3.1× 0.92%
FY2024 3.1× (19.94%)
FY2023 3.8× 28.29%
FY2022 3.0× (28.58%)
FY2021 4.2× (25.36%)
FY2020 5.6× (8.64%)
FY2019 6.1× (6.41%)
FY2018 6.5× 48.97%
FY2017 4.4× 7.55%
FY2016 4.1× (2.96%)

Quarterly newest first

Period EV/Sales Change
Jun 2026 3.0× (11.17%)
Mar 2026 3.3× 8.31%
Dec 2025 3.1× 0.92%
Sep 2025 3.1× 4.52%
42 more quarters

Against its own ten years

Low 2.3× High 8.7×
Ten-year median 4.1×
Current reading's percentile 34

EV/Sales against peers

Company EV/Sales
SNY Sanofi compare 2.0×
GSK GSK PLC Sponsored ADR compare 2.7×
BMY Bristol Myers Squibb Company compare 3.1×
PFE Pfizer Inc. 3.5×
NVO Novo Nordisk A/S compare 3.6×
AZN AstraZeneca PLC compare 4.6×
NVS Novartis AG compare 5.8×
GILD Gilead Sciences, Inc. compare 7.1×
AMGN Amgen Inc. compare 7.3×
Drug Manufacturers General industry median 4.0×
Healthcare sector median 3.4×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on PFE